Why Ablation Outperforms Drugs for Ventricular Tachycardia Post-Heart Attack: A Comprehensive Guide

Study Overview: VANISH2 Trial Findings

The VANISH2 trial studied patients with ventricular tachycardia (VT) and ischemic cardiomyopathy. The trial found that catheter ablation improved outcomes compared to antiarrhythmic drugs.

Key Results:

• After 4.3 years, patients who had catheter ablation experienced:

  • 25% fewer deaths or serious arrhythmic events (Hazard Ratio [HR] 0.75, P=0.03).
  • 25% fewer ICD shocks.
  • 74% fewer sustained VT cases.
• Death was reduced by 16%, but this comparison was not the trial’s focus.

Implications for Treatment:
Current guidelines favor using drugs before considering ablation. However, the findings suggest an earlier intervention with ablation may be more effective.

Expert Opinions:
Dr. Sana Al-Khatib and Dr. Andrea Russo emphasized that this study could change treatment approaches for patients with heart failure cardiomyopathy. Reducing ICD shocks could enhance patients’ quality of life.

Patient Population:
The trial involved 416 patients from Canada, the U.S., and France. Participants had a history of myocardial infarction and recent VT events. They were assigned to either antiarrhythmic drugs (sotalol or amiodarone) or catheter ablation within 14 days.

Outcomes Compared:

• Death rates: 22.2% (ablation) vs. 25.4% (drugs) (HR 0.84).
• Appropriate ICD shocks at 14 days: 29.6% (ablation) vs. 38.0% (drugs) (HR 0.75).
• Ventricular tachycardia storms after 14 days: 21.7% (ablation) vs. 23.5% (drugs) (HR 0.95).
• Treatment of sustained VT: 4.4% (ablation) vs. 16.4% (drugs) (HR 0.26).

Risks and Side Effects:
Serious complications from ablation and drug treatments were similar. Ablation led to:

• 1% death rate.
• 1% major bleeding.
• 1.5% stroke.

Drug treatment caused:

• 0.5% death rate.
• 3.3% lung complications.
• 3.3% overactive thyroid.

Limitations:
The study predominantly involved male participants, which may limit wider applicability. Further information is needed to understand potential crossover between treatments and the specific ablation methods used.

Funding and Disclosure:
The trial received support from various organizations, including the Canadian Institutes of Health Research. Some authors had financial ties to industry companies.

Primary Source:
Sapp JL et al., “Catheter ablation or antiarrhythmic drugs for ventricular tachycardia,” N Engl J Med 2024. DOI: 10.1056/NEJMoa2409501.